Over the past 12–18 months, the Immune Improve Dietary Supplements industry trends have been reshaped by a wave of strategic activity. In March 2024, NutriGuard partnered with TechBio Labs to embed AI‑driven microbiome analytics into its flagship elderberry‑zinc blend, promising personalized dosing recommendations. The same quarter, WellCore completed a $210 million acquisition of Immunex Labs, expanding its portfolio into clinically‑validated herbal polysaccharides. Product innovation accelerated when PureVita launched a patented “Vita‑Shield” line featuring a liposomal delivery system that boosts bioavailability of vitamin C and beta‑glucan by 45 %. Regulatory momentum arrived in July 2024 as the FDA introduced revised “Structure‑Function” labeling guidelines, allowing clearer health‑claim language for immune‑support ingredients. Consumer sentiment shifted toward clean‑label immunity boosters, driving a 22 % YoY rise in sales of plant‑based formulas. Finally, BioFusion secured a $85 million Series C round to scale its fermentation‑based vitamin D3 production, targeting Europe’s emerging “immune‑first” supplement market. In September 2024, the company also inked a distribution pact with Alibaba Health, positioning its next‑gen probiotic‑rich capsules across mainland China and Taiwan, where demand for immunity‑focused nutraceuticals is projected to outpace global averages by 2027.
